PBAC's latest decision on Siponimod: Recommended (2024). Considered for Treatment of adult patients with secondary progressive multiple sclerosis (SPMS), specifically for intermediate and extensive metabolisers requiring a 1 mg daily maintenance dose.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2019
Submissions
3
2019 → 2024
Eligible population
Adult patients with secondary progressive multiple sclerosis (SPMS) determined to have CYP2C9*2*3 or *1*3 genotype (intermediate metabolisers, approximately 12% of population) requiring a 1 mg daily maintenance dose.
Therapy area
Neurology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
siponimod 0.25 mg tablet
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated
Submission history
Nov 2019: Noted · Authority Required
Jul 2020: Recommended with restriction · Restricted